Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.14 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 2.55 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.06 | |||||
| Beneish M-Score | -2.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -33.7 | |||||
| 3-Year Book Growth Rate | -56.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 49.27 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.84 | |||||
| 9-Day RSI | 52.33 | |||||
| 14-Day RSI | 51.71 | |||||
| 6-1 Month Momentum % | 100.68 | |||||
| 12-1 Month Momentum % | 80.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.76 | |||||
| Quick Ratio | 3.66 | |||||
| Cash Ratio | 3.31 | |||||
| Days Inventory | 871.16 | |||||
| Days Sales Outstanding | 50.46 | |||||
| Days Payable | 273.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -1.99 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.58 | |||||
| Operating Margin % | -193.29 | |||||
| Net Margin % | -203.3 | |||||
| FCF Margin % | -181.61 | |||||
| ROE % | -161.12 | |||||
| ROA % | -43.47 | |||||
| ROIC % | -120.6 | |||||
| ROC (Joel Greenblatt) % | -424.32 | |||||
| ROCE % | -49.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 21.91 | |||||
| PB Ratio | 43.46 | |||||
| Price-to-Tangible-Book | 43.46 | |||||
| EV-to-EBIT | -10.62 | |||||
| EV-to-EBITDA | -10.88 | |||||
| EV-to-Revenue | 20.76 | |||||
| EV-to-Forward-Revenue | 12.95 | |||||
| EV-to-FCF | -11.43 | |||||
| Earnings Yield (Greenblatt) % | -9.42 | |||||
| FCF Yield % | -7.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BPMC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Blueprint Medicines Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 249.38 | ||
| EPS (TTM) ($) | -8.36 | ||
| Beta | 0.85 | ||
| Volatility % | 52.91 | ||
| 14-Day RSI | 51.71 | ||
| 14-Day ATR ($) | 4.285536 | ||
| 20-Day SMA ($) | 90.621 | ||
| 12-1 Month Momentum % | 80.59 | ||
| 52-Week Range ($) | 43.89 - 101 | ||
| Shares Outstanding (Mil) | 61.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Blueprint Medicines Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Blueprint Medicines Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Blueprint Medicines Corp Frequently Asked Questions
What is Blueprint Medicines Corp(BPMC)'s stock price today?
The current price of BPMC is $93.00. The 52 week high of BPMC is $101.00 and 52 week low is $43.89.
When is next earnings date of Blueprint Medicines Corp(BPMC)?
The next earnings date of Blueprint Medicines Corp(BPMC) is 2024-05-02.
Does Blueprint Medicines Corp(BPMC) pay dividends? If so, how much?
Blueprint Medicines Corp(BPMC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers